phospho cpla 2 Search Results


anti-phospho-cpla2 (ser505) polyclonal antibody  (TargetMol)
N/A
   Buy from Supplier
phosphorylated cpla2  (Cell Signaling Technology Inc)
95
Cell Signaling Technology Inc phosphorylated cpla2
Figure 5 Inhibition of 11βHSD2 activity with GA suppressed tumor growth through activation of glucocorticoid receptors. (A) GA augmented low-dose CS–induced inhibition of CT26 cell COX-2 expression. (B) Treatment with 10 mg/kg/d GA i.p. led to significant decreases in tumor size, COX-2 expression, and PGE2 levels, which were completely reversed by the glucocorticoid receptor inhibitor RU486 (7.5 mg/kg/d i.m.). n = 5–6 per group. (C) GA reduced CT26 tumor expression of phosphorylated <t>cPLA2</t> (P-cPLA2) and mPGES-1, but had no effect on tumor expression of COX-1 (P = 0.23) and cPGES (P = 0.055). Original magnification, ×400. (D) GA treatment significantly increased corticosterone levels and decreased 11-keto-corticosterone levels in kidney, colon, and tumors. n = 5. *P < 0.0001, **P < 0.001, ***P < 0.02, #P < 0.05, ##P < 0.01, and ###P < 0.005 versus vehicle.
Phosphorylated Cpla2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/phospho+cpla+2/Phospho-cPLA2+(Ser505)+Antibody/10__1172_slash_jci37398-185-53-61
Average 95 stars, based on 1 article reviews
phosphorylated cpla2 - by Bioz Stars, 2026-09
95/100 stars
  Buy from Supplier
anti phospho cpla2  (Cell Signaling Technology Inc)
93
Cell Signaling Technology Inc anti phospho cpla2
Figure 5 Inhibition of 11βHSD2 activity with GA suppressed tumor growth through activation of glucocorticoid receptors. (A) GA augmented low-dose CS–induced inhibition of CT26 cell COX-2 expression. (B) Treatment with 10 mg/kg/d GA i.p. led to significant decreases in tumor size, COX-2 expression, and PGE2 levels, which were completely reversed by the glucocorticoid receptor inhibitor RU486 (7.5 mg/kg/d i.m.). n = 5–6 per group. (C) GA reduced CT26 tumor expression of phosphorylated <t>cPLA2</t> (P-cPLA2) and mPGES-1, but had no effect on tumor expression of COX-1 (P = 0.23) and cPGES (P = 0.055). Original magnification, ×400. (D) GA treatment significantly increased corticosterone levels and decreased 11-keto-corticosterone levels in kidney, colon, and tumors. n = 5. *P < 0.0001, **P < 0.001, ***P < 0.02, #P < 0.05, ##P < 0.01, and ###P < 0.005 versus vehicle.
Anti Phospho Cpla2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/phospho+cpla+2/Phospho-cPLA2+(Ser505)+Rabbit+mAb/pmc09072365-52-5-12
Average 93 stars, based on 1 article reviews
anti phospho cpla2 - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier
anti-cpla2 (phospho-s505) pla2g4a antibody  (Boster Bio)
N/A
Boster Bio Anti-cPLA2 (phospho-S505) PLA2G4A Antibody catalog # A00854S505. Tested in WB,IHC applications. This antibody reacts with Human,Mouse,Rat.
   Buy from Supplier
anti-phospho-cpla2 (s505) antibody  (St Johns Laboratory)
N/A
Rabbit polyclonal to Phospho-cPLA2 (S505). Conjugation note: Unconjugated Application note: WB, IHC-p, IF, ELISA Reactivity note: Human, Mouse, Rat
   Buy from Supplier
phospho cpla2 ser505 polyclonal antibody  (Elabscience)
N/A
This gene encodes a member of the cytosolic phospholipase A2 group IV family The enzyme catalyzes the hydrolysis of membrane phospholipids to release arachidonic acid which is subsequently metabolized into eicosanoids Eicosanoids including prostaglandins and
   Buy from Supplier
cpla2 (phospho-ser505) antibody  (biorbyt)
N/A
Rabbit polyclonal antibody to cPLA2 (Phospho-Ser505) Isotype Note: IgG Host Note: Rabbit Conjugation Note: Unconjugated Reactivity Note: Human, Mouse, Rat Application Note: ELISA, WB, IHC-P, IF/ICC
   Buy from Supplier
cpla2 (phospho-s505) antibody  (biorbyt)
N/A
Rabbit polyclonal antibody to cPLA2 (phospho-S505). Isotype Note: IgG Host Note: Rabbit Conjugation Note: Unconjugated Reactivity Note: Human, Mouse, Rat Application Note: ELISA, WB, IHC-P, IF/ICC
   Buy from Supplier

Image Search Results


Figure 5 Inhibition of 11βHSD2 activity with GA suppressed tumor growth through activation of glucocorticoid receptors. (A) GA augmented low-dose CS–induced inhibition of CT26 cell COX-2 expression. (B) Treatment with 10 mg/kg/d GA i.p. led to significant decreases in tumor size, COX-2 expression, and PGE2 levels, which were completely reversed by the glucocorticoid receptor inhibitor RU486 (7.5 mg/kg/d i.m.). n = 5–6 per group. (C) GA reduced CT26 tumor expression of phosphorylated cPLA2 (P-cPLA2) and mPGES-1, but had no effect on tumor expression of COX-1 (P = 0.23) and cPGES (P = 0.055). Original magnification, ×400. (D) GA treatment significantly increased corticosterone levels and decreased 11-keto-corticosterone levels in kidney, colon, and tumors. n = 5. *P < 0.0001, **P < 0.001, ***P < 0.02, #P < 0.05, ##P < 0.01, and ###P < 0.005 versus vehicle.

Journal: Journal of Clinical Investigation

Article Title: Inhibition of 11β–hydroxysteroid dehydrogenase type II selectively blocks the tumor COX-2 pathway and suppresses colon carcinogenesis in mice and humans

doi: 10.1172/jci37398

Figure Lengend Snippet: Figure 5 Inhibition of 11βHSD2 activity with GA suppressed tumor growth through activation of glucocorticoid receptors. (A) GA augmented low-dose CS–induced inhibition of CT26 cell COX-2 expression. (B) Treatment with 10 mg/kg/d GA i.p. led to significant decreases in tumor size, COX-2 expression, and PGE2 levels, which were completely reversed by the glucocorticoid receptor inhibitor RU486 (7.5 mg/kg/d i.m.). n = 5–6 per group. (C) GA reduced CT26 tumor expression of phosphorylated cPLA2 (P-cPLA2) and mPGES-1, but had no effect on tumor expression of COX-1 (P = 0.23) and cPGES (P = 0.055). Original magnification, ×400. (D) GA treatment significantly increased corticosterone levels and decreased 11-keto-corticosterone levels in kidney, colon, and tumors. n = 5. *P < 0.0001, **P < 0.001, ***P < 0.02, #P < 0.05, ##P < 0.01, and ###P < 0.005 versus vehicle.

Article Snippet: Affinity-purified rabbit anti-mouse 11βHSD2 (catalog no. BHSD22-A) was purchased from Alpha Diagnostic International; rabbit anti-murine COX-2 (catalog no. 160106) and COX-1 (catalog no. 160109), rabbit anti-human mPGES-1 (catalog no. 160140) and cPGES (catalog no. 160150), and rabbit anti-rat 15-PGDH (catalog no. 160615) were from Cayman Chemicals; rabbit anti-human cPLA2 (catalog no. 2382) and phosphorylated cPLA2 (Ser505; catalog no. 2831) were from Cell Signaling; and goat anti-rat VEGF (catalog no. AF564) was from R&D Systems.

Techniques: Inhibition, Activity Assay, Activation Assay, Expressing

Figure 7 Proposed mechanism underlying 11βHSD2 activity and colorectal tumorigenesis. In tumor cells, glucocorticoids are converted to inac- tive keto-forms by 11βHSD2, reducing glucocorticoid receptor activa- tion, while inhibition of 11βHSD2 activity (by GA and its analogs or by gene knockdown) leads to increased levels of intracellular active glucocorticoids. The consequent inhibition of cPLA2 activity and COX-2 and mPGES-1 expression results in blockade of PGE2 production and inhibition of tumor growth.

Journal: Journal of Clinical Investigation

Article Title: Inhibition of 11β–hydroxysteroid dehydrogenase type II selectively blocks the tumor COX-2 pathway and suppresses colon carcinogenesis in mice and humans

doi: 10.1172/jci37398

Figure Lengend Snippet: Figure 7 Proposed mechanism underlying 11βHSD2 activity and colorectal tumorigenesis. In tumor cells, glucocorticoids are converted to inac- tive keto-forms by 11βHSD2, reducing glucocorticoid receptor activa- tion, while inhibition of 11βHSD2 activity (by GA and its analogs or by gene knockdown) leads to increased levels of intracellular active glucocorticoids. The consequent inhibition of cPLA2 activity and COX-2 and mPGES-1 expression results in blockade of PGE2 production and inhibition of tumor growth.

Article Snippet: Affinity-purified rabbit anti-mouse 11βHSD2 (catalog no. BHSD22-A) was purchased from Alpha Diagnostic International; rabbit anti-murine COX-2 (catalog no. 160106) and COX-1 (catalog no. 160109), rabbit anti-human mPGES-1 (catalog no. 160140) and cPGES (catalog no. 160150), and rabbit anti-rat 15-PGDH (catalog no. 160615) were from Cayman Chemicals; rabbit anti-human cPLA2 (catalog no. 2382) and phosphorylated cPLA2 (Ser505; catalog no. 2831) were from Cell Signaling; and goat anti-rat VEGF (catalog no. AF564) was from R&D Systems.

Techniques: Activity Assay, Inhibition, Knockdown, Expressing